| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8524773 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(6 years ago) | |
| US8759393 | BIOGEN INC | Utilization of dialkylfumarates |
Jul, 2018
(5 years ago) | |
| US6509376 | BIOGEN INC | Utilization of dialkyfumarates |
Apr, 2019
(5 years ago) | |
| US7803840 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2019
(5 years ago) | |
| US7320999 | BIOGEN INC | Dimethyl fumarate for the treatment of multiple sclerosis |
Oct, 2019
(4 years ago) | |
| US7619001 | BIOGEN INC | Utilization of dialkylfumarates |
Jun, 2020
(3 years ago) | |
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(3 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(10 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
| US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(11 years from now) | |
Tecfidera is owned by Biogen Inc.
Tecfidera contains Dimethyl Fumarate.
Tecfidera has a total of 15 drug patents out of which 6 drug patents have expired.
Expired drug patents of Tecfidera are:
- US8524773
- US8759393
- US6509376
- US7803840
- US7320999
- US7619001
Tecfidera was authorised for market use on 27 March, 2013.
Tecfidera is available in capsule, delayed release;oral dosage forms.
Tecfidera can be used as method of treating multiple sclerosis, method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis, method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine.
Drug patent challenges can be filed against Tecfidera from 27 March, 2017.
The generics of Tecfidera are possible to be released after 16 November, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-260) | Feb 05, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating multiple sclerosis; Method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis; Method of treating r...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TECFIDERA family patents
